中药苷类化合物防治骨不愈合作用机制研究进展  

Research Progress in the Mechanisms of Glycoside Compounds of Chinese Medicinals in the Prevention and Treatment of Bone Nonunion Bone

作　　者：张进学 申建军[2] 沈尚中 张津 薛盛中 陈志伟[2] 周文杰 ZHANG Jinxue;SHEN Jianjun;SHEN Shangzhong;ZHANG Jin;XUE Shengzhong;CHEN Zhiwei;ZHOU Wenjie(Gansu University of Chinese Medicine,Lanzhou,Gansu,China,730000;Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou,Gansu 730050)

机构地区：[1]甘肃中医药大学,甘肃兰州730000 [2]甘肃省中医院,甘肃兰州730050

出　　处：《河南中医》2024年第12期1939-1944,共6页Henan Traditional Chinese Medicine

基　　金：甘肃省自然科学基金项目(23JRRA1680)。

摘　　要：中药苷类化合物治疗骨不愈合的机制主要包括促进成骨细胞分化、抑制破骨细胞生成、促进新生血管生成、抑制炎症反应等,能够通过多途径、多靶点和多效性的治疗策略,实现促进骨质生成与抑制骨质破坏等多重目标。但目前研究仍存在诸多不足,如机制研究不够深入、缺乏大规模临床试验、药物递送系统不完善、未充分考虑个体差异以及长期不良反应不明确等。今后,应深入探索其分子机制,开展临床试验验证疗效和安全性,改进药物递送系统,考虑个体化治疗,评估长期不良反应,并探索与其他治疗方法的联合应用,为临床治疗骨折不愈合开辟新的策略和视角。The mechanisms by which glycoside compounds of Chinese medicinals treat bone nonunion include promoting osteoblast differentiation,inhibiting osteoclast formation,enhancing angiogenesis,and reducing inflammatory responses,etc.These compounds achieve multiple therapeutic objectives through multi-pathway,multi-target,and multi-efficacy strategies to promote bone formation and inhibit bone destruction,etc.However,current research faces limitations,such as insufficient depth in mechanistic studies,lack of large-scale clinical trials,inadequate drug delivery systems,lack of consideration for individual variability,and unclear long-term side effects.Future studies should focus on in-depth exploration of molecular mechanisms,clinical trials to validate efficacy and safety,improvements in drug delivery systems,personalized treatments,evaluation of long-term side effects,and potential integration with other therapies.These efforts may open new strategies and perspectives for clinical treatment of bone nonunion.

关 键 词：中药苷类化合物 骨折 骨不愈合 成骨细胞 

分 类 号：R274.1[医药卫生—中医骨伤科学]